Wegovy maker Novo Nordisk sues rival over ‘knock-off’ weight-loss drugs.

Danish pharmaceutical giant Novo Nordisk, the pioneering force behind the highly sought-after weight-loss medications Ozempic and Wegovy, has initiated legal proceedings against US-based telehealth company Hims & Hers. The lawsuit, filed in US courts, accuses Hims & Hers of manufacturing and selling "unsafe, knock-off" versions of its blockbuster weight-loss drugs, specifically targeting compounded semaglutide products. Novo Nordisk is seeking a judicial order to ban Hims & Hers’ range of weight-loss pills and injections, asserting that these products are neither approved by US authorities nor do they adhere to the stringent safety and efficacy standards required for prescription medications. Furthermore, the pharmaceutical firm alleges that Hims & Hers’ offerings infringe upon its established patents for semaglutide, the active ingredient in Ozempic and Wegovy.

The legal battle escalated swiftly, beginning with Hims & Hers’ announcement on a Friday of its new line of weight-loss pills. This launch was met almost immediately with a stern threat of legal action from Novo Nordisk. Over the subsequent weekend, in an apparent attempt to de-escalate the situation or perhaps mitigate potential damages, Hims & Hers publicly stated its intention to cease selling the newly launched pill. However, this concession did not deter Novo Nordisk, which proceeded with filing its lawsuit on the following Monday. The news sent ripples through the stock market, with Hims & Hers’ shares plummeting by 16% on Monday, while Novo Nordisk’s share price saw a slight uptick early on Tuesday, reflecting investor reactions to the unfolding legal drama. Hims & Hers vehemently responded to the lawsuit, characterizing Novo Nordisk’s decision to press ahead with legal action as a "blatant attack" on consumer choice and a misuse of the judicial system.

The meteoric rise of weight-loss drugs like Novo Nordisk’s Ozempic and Wegovy, and increasingly Eli Lilly’s Zepbound and Mounjaro, has reshaped the pharmaceutical landscape over the last few years. These medications, classified as GLP-1 receptor agonists, work by mimicking a natural hormone that helps regulate blood sugar and appetite, leading to significant weight loss in many patients. Ozempic was initially approved for Type 2 diabetes management, while Wegovy received specific FDA approval for chronic weight management. Their unprecedented demand has not only driven immense financial success for their manufacturers but also highlighted a significant unmet need in the treatment of obesity.

Novo Nordisk’s official statement on Monday underscored its rationale for the lawsuit, emphasizing its commitment to "protect public health and defend the scientific innovations that deliver better health outcomes to Americans." This stance frames the legal action not merely as a commercial dispute but as a crucial safeguard against potentially harmful products entering the market. In contrast, Hims & Hers countered by asserting its "long history of providing safe access to personalized healthcare to millions of Americans." The company’s accusation that Novo Nordisk is "weaponizing the US judicial system to limit consumer choice" reflects a broader tension between intellectual property rights, pharmaceutical innovation, and the desire for more affordable and accessible healthcare solutions, especially in a market with high demand and often limited supply of branded drugs.

Industry experts are closely monitoring the case. Kerry Fulford, a pharmaceutical analyst at Berenberg, observed to the BBC that this lawsuit represents the "first move Novo Nordisk is making to clamp down on compounding." Compounding is a long-established and legal process in the US, allowing licensed pharmacists or physicians to combine, mix, or alter ingredients to create a medication tailored to the individual needs of a patient. This practice is typically reserved for situations where a patient cannot take a commercially available drug due to allergies, specific dosage requirements, or, critically in this context, when a drug is in short supply. Hims & Hers’ weight-loss drugs are compounded versions, while Novo Nordisk’s are standardized, FDA-approved formulations.

However, the legality and safety of compounding, particularly for highly popular and patented drugs like semaglutide, have become contentious. The US Food and Drug Administration (FDA) has expressed significant concerns regarding compounded versions of GLP-1 receptor agonists. The agency has specifically warned against compounded semaglutide that uses the salt form, semaglutide sodium, rather than the base form, semaglutide, which is the active ingredient in Ozempic and Wegovy. The FDA has clarified that semaglutide sodium is not the same active ingredient and has not been evaluated for safety and efficacy. Additionally, compounded drugs are not subject to the same rigorous FDA review process as commercially manufactured drugs. This means there’s no guarantee of their purity, potency, or sterility.

Novo Nordisk’s lawsuit explicitly referenced these FDA concerns, stating that Hims & Hers’ compounded drugs "may contain dangerous impurities or incorrect amounts of active ingredients, which can result in life-threatening immune responses." This highlights the potential for serious health risks, including allergic reactions, infections, or ineffective treatment, if patients receive a product that is not properly manufactured or contains incorrect components. "This is Novo’s way of fighting back," Fulford elaborated, suggesting that the pharmaceutical giant is drawing a clear line in the sand against practices it perceives as undermining patient safety and its intellectual property.

The high demand for Ozempic and Wegovy, which has frequently led to supply shortages, has inadvertently created a fertile ground for compounding pharmacies to offer alternatives. While compounding can serve a vital role for individualized patient care, the proliferation of compounded GLP-1s has raised alarms among regulatory bodies and original manufacturers who argue that such practices exploit drug shortages and bypass critical safety checks. The FDA’s stance is that while compounding is permissible under specific circumstances, it should not be a workaround for drug shortages of approved products if those products are readily available, nor should it be used to create copies of FDA-approved drugs.

Adding another layer of complexity to the narrative, Novo Nordisk itself has recently faced scrutiny from the FDA regarding its marketing practices. Just days before filing the lawsuit against Hims & Hers, the agency sent Novo Nordisk a letter on a Thursday, flagging concerns about a TV advertisement for its Wegovy pill. The FDA asserted that the ad "misleadingly impl[ies] benefits beyond physical weight loss such as emotional relief, reduced psychological burden, hope, or direction for patients’ lives." The FDA, which rigorously regulates drug advertising to ensure claims are accurate and not misleading, took issue with the broader, more emotional promises suggested by the advertisement, which could potentially set unrealistic expectations for patients. In response, Novo Nordisk stated it "takes all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation." This parallel regulatory action against Novo Nordisk highlights the intense scrutiny surrounding the entire weight-loss drug market, from production and distribution to marketing and patient access.

The outcome of this lawsuit could have far-reaching implications. For Novo Nordisk, a victory would reinforce its patent protection and potentially deter other telehealth platforms or compounding pharmacies from offering similar "knock-off" versions of its drugs. This would safeguard its market share and significant investments in research and development. For Hims & Hers, a loss could severely impact its business model and its ability to offer a broader range of personalized healthcare solutions. More broadly, the case will likely set a precedent for the entire pharmaceutical industry and the rapidly expanding telehealth sector, influencing how compounded medications are regulated and accessed, especially for high-demand, high-cost drugs. It also reignites the ongoing debate about the balance between protecting pharmaceutical innovation through patents and ensuring affordable, safe access to essential medications for a wide patient population. As the legal battle unfolds, it underscores the complex interplay of commercial interests, public health concerns, and regulatory oversight in the burgeoning market for weight-loss treatments.